Blog

A liver biopsy is a procedure to obtain small samples of liver tissue for microscopic examination. Three main techniques – percutaneous liver biopsy (most common; needle inserted through skin; ultrasound or CT guidance; local anesthesia; biopsy gun obtains tissue cores; 15-30 minutes; recovery 4-6 hours); transjugular liver biopsy (needle through jugular vein in neck, advanced to hepatic vein; for patients with bleeding risk or ascites; performed in interventional radiology); surgical/laparoscopic liver biopsy (during other abdominal surgery; visual selection of biopsy site). Tissue analysis – pathologist examines tissue for fat content (steatosis), inflammation, fibrosis (scarring), ballooning hepatocytes, other features. Grading – NAFLD activity score (NAS), fibrosis stage (F0-F4 where F4 is cirrhosis). For diabetes patients – typically percutaneous biopsy; performed if diagnostic uncertainty or to confirm advanced disease before treatment decisions. NAFLD (non-alcoholic fatty liver disease) is metabolic liver disease intimately tied to diabetes. Prevalence – about 70% of adults with type 2 diabetes have NAFLD; 30% have NASH (non-alcoholic steatohepatitis – more severe form with inflammation and damage); about 5-10% develop cirrhosis. Pathophysiology – insulin resistance drives fat accumulation in liver; chronic inflammation; oxidative stress; can progress to fibrosis and cirrhosis. Risk factors – obesity (especially central), insulin resistance, type 2 diabetes, metabolic syndrome, polycystic ovary syndrome, dyslipidemia, hypertension. Spectrum – simple fatty liver (steatosis), NASH, fibrosis, cirrhosis, hepatocellular carcinoma. Liver disease leading cause of liver transplantation in U.S. now (was hepatitis C historically). 2023 – NAFLD renamed MAFLD/MASLD (metabolic-associated/metabolic-dysfunction-associated steatotic liver disease) – more accurate term reflecting metabolic basis. Specific clinical situations indicate biopsy. Increasingly replaced by non-invasive testing. Indications – diagnostic uncertainty (distinguish NAFLD from other liver diseases); suspected advanced fibrosis (to confirm before treatment decisions); pre-treatment evaluation; unexplained liver enzyme elevation; suspected hepatocellular carcinoma evaluation; post-transplant rejection or recurrent disease. Non-invasive alternatives – FIB-4 score (calculator using age, AST, ALT, platelets; estimates fibrosis); NAFLD Fibrosis Score (NFS); FibroScan (vibration-controlled transient elastography – ultrasound-based measurement of liver stiffness); magnetic resonance elastography (MRE – most accurate non-invasive); Enhanced Liver Fibrosis (ELF) test – blood biomarkers. For diabetes patients – typically start with FIB-4 score; if intermediate-high risk, FibroScan; biopsy if needed for diagnostic certainty or trial enrollment.

NAFLD Spectrum and Fibrosis Stages

NAFLD/MASLD in Type 2 Diabetes

Non-Invasive Alternatives (Less Invasive than Biopsy)

• FIB-4 score – free online calculator; AST, ALT, age, platelets.
• NAFLD Fibrosis Score (NFS) – similar calculator.
• FibroScan – ultrasound-based liver stiffness; widely available.
• FibroScan CAP – measures liver fat content.
• Magnetic resonance elastography (MRE) – most accurate; expensive.
• MR-PDFF – measures liver fat by MRI.
• Enhanced Liver Fibrosis (ELF) test – blood biomarkers.
• FibroSure (FibroTest) – blood-based score.
• Pro-C3 – newer blood biomarker.
• Combination approaches – FIB-4 + FibroScan increasingly standard.

Liver Biopsy Indications

• Diagnostic uncertainty about cause of liver disease.
• Discrepant non-invasive testing results.
• Confirm advanced fibrosis before treatment.
• Clinical trial enrollment (often requires biopsy).
• Unexplained liver enzyme elevation.
• Suspected drug-induced liver injury.
• Distinguishing autoimmune hepatitis from NASH.
• Post-transplant rejection evaluation.
• Suspected hepatocellular carcinoma.

What to Expect During Biopsy

• Hold blood thinners several days before per provider.
• Check INR if on warfarin.
• Fast 4-8 hours before.
• Arrange ride home.
• Lie on back with right arm extended overhead.
• Local anesthetic injected (brief burning).
• Ultrasound guides needle.
• Biopsy gun rapidly obtains tissue (loud click; brief pressure).
• Multiple cores taken (3-4).
• Procedure 15-30 minutes.
• Recovery 4-6 hours observation.
• Lie on right side 2 hours after.
• Discharge same day usually.
• Mild discomfort 1-3 days at biopsy site.
• Avoid strenuous activity 24-48 hours.

Diabetes and Liver Health

• Weight loss most effective for NAFLD/NASH (7-10% body weight target).
• Mediterranean diet pattern recommended.
• Avoid alcohol or limit strictly.
• Avoid sugar-sweetened beverages.
• Regular exercise (150+ min/week moderate).
• GLP-1 agonists (semaglutide, tirzepatide) – help with weight loss and may improve NASH.
• SGLT2 inhibitors – some evidence for liver benefit.
• Pioglitazone – some NASH benefit but weight gain.
• Vitamin E – some benefit in non-diabetic NASH.
• Resmetirom – FDA-approved for NASH (2024).
• Annual FIB-4 calculation for diabetes patients.
• Vaccination – hepatitis A and B if susceptible.

The Bottom Line

A liver biopsy is a procedure to obtain small samples of liver tissue for microscopic examination. Three main techniques – percutaneous liver biopsy (most common); transjugular liver biopsy (for patients with bleeding risk or ascites); surgical/laparoscopic liver biopsy (during other abdominal surgery). Tissue analysis – pathologist examines tissue for fat content (steatosis), inflammation, fibrosis (scarring), ballooning hepatocytes, other features. Grading – NAFLD activity score (NAS), fibrosis stage (F0-F4 where F4 is cirrhosis). For diabetes patients – typically percutaneous biopsy; performed if diagnostic uncertainty or to confirm advanced disease before treatment decisions. NAFLD (non-alcoholic fatty liver disease) is metabolic liver disease intimately tied to diabetes. About 70% of adults with type 2 diabetes have NAFLD; 30% have NASH; about 5-10% develop cirrhosis. Pathophysiology – insulin resistance drives fat accumulation in liver; chronic inflammation; oxidative stress; can progress to fibrosis and cirrhosis. Risk factors – obesity (especially central), insulin resistance, type 2 diabetes, metabolic syndrome, PCOS, dyslipidemia, hypertension. Spectrum – simple fatty liver, NASH, fibrosis, cirrhosis, hepatocellular carcinoma. Liver disease is now leading cause of liver transplantation in U.S. 2023 – NAFLD renamed MAFLD/MASLD – more accurate term reflecting metabolic basis. Liver biopsy increasingly replaced by non-invasive testing. Indications – diagnostic uncertainty; suspected advanced fibrosis to confirm before treatment; pre-treatment evaluation; unexplained liver enzyme elevation; suspected hepatocellular carcinoma evaluation. Non-invasive alternatives – FIB-4 score (calculator using age, AST, ALT, platelets); NAFLD Fibrosis Score; FibroScan (vibration-controlled transient elastography – ultrasound-based measurement of liver stiffness); magnetic resonance elastography (MRE – most accurate non-invasive); Enhanced Liver Fibrosis (ELF) test. For diabetes patients – typically start with FIB-4 score; if intermediate-high risk, FibroScan; biopsy if needed. Half-day procedure with home recovery. Preparation – hold blood thinners; check INR if on warfarin; fasting 4-8 hours before; arrange ride home. Procedure – local anesthetic, ultrasound-guided needle, biopsy gun for tissue cores, 15-30 minutes. Recovery – lie on right side 2 hours, then on back 2 more hours; 4-6 hours observation. Complications rare but possible – bleeding (1-3%), pain, bile leak, infection, pneumothorax. NAFLD/NASH management – weight loss most effective (7-10% body weight target); Mediterranean diet; avoid alcohol; exercise; GLP-1 agonists for weight loss and possible NASH benefit; SGLT2 inhibitors with some liver benefit; pioglitazone NASH benefit but weight gain; Vitamin E in non-diabetic NASH; Resmetirom FDA-approved for NASH 2024. For adults with type 2 diabetes – regular liver screening with FIB-4 score recommended; FibroScan for intermediate-high risk; biopsy reserved for diagnostic uncertainty or trial enrollment; weight loss and good diabetes management most important interventions. See our broader fatty liver disease guide for context.

HIDA scan (hepatobiliary iminodiacetic acid scan, also called cholescintigraphy) uses a radioactive tracer to evaluate the function of liver, gallbladder, and bile ducts. Procedure – patient lies on imaging table; radioactive tracer (technetium-99m labeled with HIDA compound) injected into vein; tracer absorbed by liver, secreted into bile; gamma camera captures images as tracer moves through liver, into gallbladder, and into small intestine; standard test 60-90 minutes; possible CCK injection – cholecystokinin medication injected to stimulate gallbladder contraction, measures ejection fraction (normal greater than 38%), takes 30 additional minutes. Total study 60-120 minutes. Information provided – bile duct patency, gallbladder visualization, gallbladder ejection fraction (functional capacity), leak detection (post-surgery), acute cholecystitis. Indications – when ultrasound normal but symptoms suggest gallbladder disease (functional gallbladder disease); acute cholecystitis evaluation; biliary leak after surgery; pediatric biliary atresia; sphincter of Oddi dysfunction. For diabetes patients – useful diagnostic tool for vague upper abdominal symptoms. Multiple risk factors for gallbladder issues in diabetes. Adults with diabetes have 2-3x higher gallstone risk than general population. Possible mechanisms – obesity (shared risk factor; major driver); hyperinsulinemia (promotes cholesterol secretion into bile; increases gallstone formation); diabetic gallbladder dysmotility (delayed emptying – autonomic neuropathy); hypertriglyceridemia (common in diabetes; affects bile composition); rapid weight loss (significant trigger; particularly with bariatric surgery or GLP-1 agonists); GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide – FDA labeling notes increased gallbladder disease risk – about 0.5-1% absolute risk increase per year). Common presentation in diabetes – asymptomatic gallstones common (50-70% of diabetic patients with gallstones have no symptoms); when symptomatic – right upper quadrant pain, especially after fatty meals; nausea, vomiting; pain radiating to back/shoulder. Gallbladder ejection fraction (GBEF) – percentage of bile expelled when gallbladder contracts; measured after CCK injection during HIDA scan. Normal greater than 38%; abnormal less than 38% suggests functional gallbladder disease.

HIDA Scan Indications

HIDA Scan Results

Diabetes Gallbladder Risk Factors

• Obesity – shared risk factor; major driver.
• Hyperinsulinemia promotes cholesterol secretion into bile.
• Diabetic gallbladder dysmotility (autonomic neuropathy).
• Hypertriglyceridemia affects bile composition.
• Rapid weight loss (especially bariatric surgery, GLP-1 agonists).
• GLP-1 receptor agonists – FDA labeling notes increased risk.
• Female sex (women higher gallstone risk anyway).
• Age (gallstones more common with age).
• Family history of gallstones.
• Native American ethnicity (higher gallstone risk).

Gallbladder Symptoms to Recognize

• Right upper quadrant pain, especially after fatty meals.
• Pain may radiate to right shoulder or back.
• Nausea and vomiting.
• Episodic pain (biliary colic).
• Fever (suggests infection – cholecystitis).
• Jaundice (yellow skin/eyes – bile duct obstruction).
• Clay-colored stools (bile not reaching intestine).
• Dark urine (bile in urine).
• Indigestion, bloating.
• Belching.

Diagnostic Workup

• Ultrasound first – shows gallstones; cheap, non-invasive.
• HIDA scan if ultrasound normal but symptoms persist.
• CT abdomen – alternative imaging.
• MRCP – magnetic resonance imaging of bile ducts.
• ERCP – therapeutic and diagnostic for bile duct stones.
• Liver function tests – check for elevated alkaline phosphatase, bilirubin.
• Lipase/amylase – rule out pancreatitis.
• Endoscopic ultrasound – for some indications.

Treatment Options

• Asymptomatic gallstones – usually no treatment in diabetes.
• Symptomatic gallstones – cholecystectomy (laparoscopic preferred).
• Acute cholecystitis – admission, IV antibiotics, often cholecystectomy.
• Functional gallbladder disease – cholecystectomy if confirmed by HIDA.
• Bile duct stones – ERCP for stone removal.
• Dietary modification – low-fat diet, weight management.
• Ursodeoxycholic acid (Actigall) – dissolves cholesterol stones; long process.
• Address GLP-1 agonist if iatrogenic gallbladder disease.
• Cholecystectomy outcomes in diabetes – slightly higher complication rate.

The Bottom Line

HIDA scan (hepatobiliary iminodiacetic acid scan, also called cholescintigraphy) uses a radioactive tracer to evaluate the function of liver, gallbladder, and bile ducts. Procedure – radioactive tracer injected into vein; tracer absorbed by liver, secreted into bile; gamma camera captures images as tracer moves through liver, into gallbladder, and into small intestine; standard test 60-90 minutes; possible CCK injection to stimulate gallbladder contraction (measures ejection fraction). Total study 60-120 minutes. Information provided – bile duct patency, gallbladder visualization, gallbladder ejection fraction, leak detection, acute cholecystitis. Indications – when ultrasound normal but symptoms suggest gallbladder disease (functional gallbladder disease); acute cholecystitis evaluation; biliary leak after surgery; sphincter of Oddi dysfunction. Multiple risk factors for gallbladder issues in diabetes. Adults with diabetes have 2-3x higher gallstone risk than general population. Possible mechanisms – obesity (shared risk factor; major driver); hyperinsulinemia (promotes cholesterol secretion into bile); diabetic gallbladder dysmotility (delayed emptying – autonomic neuropathy); hypertriglyceridemia; rapid weight loss (significant trigger; particularly with bariatric surgery or GLP-1 agonists); GLP-1 receptor agonists (FDA labeling notes increased gallbladder disease risk – about 0.5-1% absolute risk increase per year). Common presentation in diabetes – asymptomatic gallstones common (50-70% of diabetic patients with gallstones have no symptoms); when symptomatic – right upper quadrant pain, especially after fatty meals; nausea, vomiting; pain radiating to back/shoulder. Gallbladder ejection fraction (GBEF) – percentage of bile expelled when gallbladder contracts; measured after CCK injection during HIDA scan. Normal greater than 38%; abnormal less than 38% suggests functional gallbladder disease (biliary dyskinesia). Functional gallbladder disease – gallbladder symptoms (right upper quadrant pain, nausea after meals) without gallstones; reduced ejection fraction on HIDA; some patients improve with cholecystectomy. Treatment – asymptomatic gallstones usually no treatment in diabetes; symptomatic gallstones – cholecystectomy (laparoscopic preferred); acute cholecystitis – admission, IV antibiotics, often cholecystectomy; functional gallbladder disease – cholecystectomy if confirmed by HIDA; dietary modification (low-fat diet, weight management); address GLP-1 agonist if iatrogenic gallbladder disease. For adults with type 2 diabetes – elevated gallbladder disease risk; HIDA useful when ultrasound normal but symptoms persist; GLP-1 agonist users should be aware of FDA label warning; report new gallbladder symptoms promptly. See our broader prediabetes detection guide.

Gastric emptying scintigraphy is the gold-standard test for gastroparesis – delayed emptying of food from stomach to small intestine. Procedure – patient eats standardized meal (typically egg sandwich or other solid meal) labeled with small amount of radioactive tracer (technetium-99m sulfur colloid); patient stands or sits in front of gamma camera; images taken at 0, 1, 2, and 4 hours after meal; computer calculates percentage of meal remaining in stomach at each time point; total study about 4 hours. Normal results – less than 10% retention at 4 hours. Abnormal (gastroparesis) – more than 10% at 4 hours (mild), more than 25% (moderate), more than 50% (severe). Other tests – breath tests (13C-octanoic acid, 13C-spirulina) measure breath isotopes; less common; comparable accuracy. Wireless motility capsule (SmartPill) – swallowed capsule measures pressure, pH, temperature; alternative non-radioactive option. For diabetes patients – typical recommendation if symptoms suggestive (nausea, early satiety, vomiting, postprandial fullness, unexplained glycemic variability). Delayed stomach emptying due to nerve damage. Pathophysiology – chronic hyperglycemia damages vagus nerve (autonomic neuropathy) controlling stomach motility; food empties slowly from stomach; affects 5-50% of long-duration diabetes (variable estimates depending on definition; many cases mild and asymptomatic). Symptoms – nausea, vomiting, early satiety (feel full after few bites), postprandial fullness, abdominal pain, bloating, weight loss, GERD-like symptoms, anorexia. Diabetes-specific impact – erratic blood sugar (mismatch between insulin timing and food absorption); difficult medication timing; bezoars (food masses in stomach); malnutrition; severely impaired quality of life in severe cases. Predisposing factors – long-duration diabetes (10+ years), poorly controlled blood sugar, other diabetic complications (retinopathy, nephropathy, neuropathy), female sex, type 1 more than type 2 traditionally. GLP-1 receptor agonists (semaglutide, tirzepatide, others) cause functional gastroparesis – usually transient but can be persistent in some; not true diabetic gastroparesis but similar symptoms.

Test Result Categories

Gastroparesis Symptoms

• Nausea (most common).
• Vomiting (sometimes hours after eating).
• Early satiety (feel full after few bites).
• Postprandial fullness/bloating.
• Abdominal pain (variable).
• Weight loss (if severe).
• Heartburn/GERD-like symptoms.
• Anorexia.
• Unexplained blood sugar variability.
• Frequent post-meal hypoglycemia (insulin acts before food absorbed).
• Difficulty taking oral medications.
• Bad breath (food retention).

Indications for Test

• Symptoms suggestive of gastroparesis.
• Unexplained glycemic variability in diabetes.
• Newly intolerant of previously tolerated foods.
• Failed lifestyle/dietary management of GI symptoms.
• Before starting prokinetic medications.
• Refractory GERD without other explanation.
• Differential diagnosis of nausea/vomiting.
• Pre-bariatric surgery evaluation (some surgeons).

Test Preparation

• Off prokinetics 48 hours (Reglan, erythromycin, etc.).
• Off opioids 48 hours if possible.
• Discuss GLP-1 agonist hold with prescriber (may not need to hold for chronic users).
• Hold anticholinergics.
• Fast overnight (8+ hours).
• Blood sugar should be 60-275 mg/dL on day of test.
• Pregnancy test if female of reproductive age.
• Bring list of medications.
• Plan 4-5 hours total time at facility.
• Eat standardized test meal at clinic.

Treatment Approaches

• Glycemic control – well-controlled diabetes slows progression.
• Small frequent meals (5-6 daily) instead of 3 large.
• Low-fat diet (fat delays emptying).
• Low-fiber diet (fiber forms bezoars in stomach).
• Liquids easier to digest than solids.
• Chew thoroughly; eat slowly.
• Avoid carbonated drinks, alcohol.
• Don’t lie down immediately after eating.
• Prokinetic medications – metoclopramide (Reglan), erythromycin, domperidone.
• Antiemetics for nausea – ondansetron, prochlorperazine.
• Avoid opioid pain medications (worsen gastroparesis).
• Gastric electrical stimulation (Enterra) for refractory cases.
• Pylorus-directed therapies – Botox, G-POEM.
• Feeding tube (jejunostomy) for severe cases.
• Address GLP-1 agonist if iatrogenic.

Diabetes Management with Gastroparesis

• CGM device essential – shows erratic glucose patterns.
• Adjust insulin timing – shorter time before meals for rapid-acting.
• Consider extended-action insulin formulations.
• Smaller frequent insulin doses may work better.
• Avoid sulfonylureas if frequent hypoglycemia.
• SGLT2 inhibitors generally safe; some GI side effects.
• Metformin GI symptoms may overlap.
• Address vagal nerve function via blood sugar control.
• Vitamin/mineral supplementation (deficiencies common).
• Liquid nutrition supplements may be needed.

The Bottom Line

Gastric emptying scintigraphy is the gold-standard test for gastroparesis – delayed emptying of food from stomach to small intestine. Procedure – patient eats standardized meal labeled with small amount of radioactive tracer (technetium-99m); images taken at 0, 1, 2, and 4 hours after meal; computer calculates percentage of meal remaining at each time point; total study about 4 hours. Normal results – less than 10% retention at 4 hours. Abnormal – more than 10% (mild), more than 25% (moderate), more than 50% (severe). Other tests – breath tests, wireless motility capsule (SmartPill). For diabetes patients – typical recommendation if symptoms suggestive (nausea, early satiety, vomiting, postprandial fullness, unexplained glycemic variability). Delayed stomach emptying due to nerve damage. Pathophysiology – chronic hyperglycemia damages vagus nerve (autonomic neuropathy) controlling stomach motility; affects 5-50% of long-duration diabetes (many cases mild and asymptomatic). Symptoms – nausea, vomiting, early satiety, postprandial fullness, abdominal pain, bloating, weight loss, GERD-like symptoms, anorexia. Diabetes-specific impact – erratic blood sugar (mismatch between insulin timing and food absorption); difficult medication timing; bezoars; malnutrition; severely impaired quality of life in severe cases. Predisposing factors – long-duration diabetes (10+ years), poorly controlled blood sugar, other diabetic complications, female sex, type 1 more than type 2. GLP-1 receptor agonists (semaglutide, tirzepatide) cause functional gastroparesis. Indications for test – symptoms suggestive of gastroparesis; unexplained glycemic variability; newly intolerant of foods previously tolerated; failed lifestyle/dietary management of GI symptoms; before starting prokinetic medications; differential diagnosis of unexplained nausea/vomiting; refractory GERD. Pre-test requirements – off prokinetics 48 hours; off opioids 48 hours; off GLP-1 agonists if possible (discuss with prescriber); fast overnight; blood sugar 60-275 mg/dL; pregnancy testing if applicable. Treatment – glycemic control; dietary modification (small frequent meals, low-fat, low-fiber, liquids); medications (prokinetics, antiemetics, pain management avoiding opioids); gastric electrical stimulation (Enterra) for refractory cases; pylorus-directed therapies; severe cases – jejunostomy feeding tube. Diabetes management with gastroparesis – CGM essential; adjust insulin timing; smaller frequent doses; avoid sulfonylureas if frequent hypoglycemia. For adults with type 2 diabetes – gastroparesis is underrecognized; consider testing if symptoms or unexplained glycemic variability; treatment is multifaceted; address GLP-1 agonist use if iatrogenic. See our broader diabetic neuropathy guide for context.

Helicobacter pylori (H pylori) is a spiral-shaped bacterial infection of the stomach lining; one of the most common chronic infections worldwide. Prevalence – about 30-40% of U.S. adults; 50-70% in developing countries; often acquired in childhood. Most infections asymptomatic but can cause peptic ulcers (gastric, duodenal); chronic gastritis; gastric cancer (H pylori is Class I carcinogen); MALT lymphoma; possibly iron-deficiency anemia; possibly idiopathic thrombocytopenic purpura (ITP); functional dyspepsia in some. Indications for testing – active peptic ulcer disease; history of peptic ulcers; dyspepsia in adults under 60 without alarm features; long-term NSAID or aspirin therapy; family history of gastric cancer; gastric MALT lymphoma; unexplained iron-deficiency anemia; ITP. Test before treating long-term NSAID users; consider in immigrants from high-prevalence countries with dyspepsia. After treatment – “test of cure” 4 weeks after antibiotic completion to confirm eradication. Multiple test methods – urea breath test (patient swallows urea labeled with carbon isotope; H pylori urease enzyme converts to labeled CO2; very accurate 95% sensitivity/specificity; good for diagnosis and test of cure); stool antigen test (detects H pylori antigens; very accurate; convenient); blood antibody test (serology – detects IgG antibodies; widely available; cheap; BUT can’t distinguish active vs past infection; not for test of cure); endoscopy with biopsy (most invasive; for symptoms warranting endoscopy). Preparation requirements – urea breath test and stool antigen need to be off PPIs 2 weeks, off antibiotics 4 weeks, off bismuth 4 weeks (false negatives). Serology not affected. Best initial test typically – urea breath test or stool antigen for non-invasive cases. Emerging research area with mixed evidence. Some studies suggest higher H pylori prevalence in adults with type 2 diabetes (about 1.5x more common); H pylori infection associated with worse glycemic control; eradication may modestly improve A1C; possible link to insulin resistance. Mechanisms proposed – chronic inflammation affecting insulin sensitivity; gut microbiome changes; effect on incretin hormones (GLP-1, GIP); altered absorption of nutrients. However – evidence inconsistent; routine screening NOT currently recommended just because of diabetes. American Diabetes Association does not recommend routine H pylori screening for asymptomatic diabetes patients.

H Pylori Test Options

Indications for Testing

• Active peptic ulcer disease (PUD).
• History of peptic ulcers.
• Dyspepsia in adults under 60 (without alarm features).
• Long-term NSAID or aspirin therapy.
• Family history of gastric cancer.
• Gastric MALT lymphoma.
• Unexplained iron-deficiency anemia.
• Idiopathic thrombocytopenic purpura (ITP).
• Immigrants from high-prevalence countries with dyspepsia.
• Before long-term NSAID therapy.
• Functional dyspepsia after failure of other treatments.
• Test of cure after treatment.

Treatment Regimens

• Bismuth quadruple therapy (preferred first-line in many regions) – PPI + bismuth subsalicylate + tetracycline + metronidazole for 10-14 days.
• Clarithromycin triple therapy (where resistance is low) – PPI + clarithromycin + amoxicillin for 14 days.
• Concomitant therapy – PPI + amoxicillin + clarithromycin + metronidazole for 10-14 days.
• Sequential therapy – 5 days of PPI + amoxicillin, then 5 days PPI + clarithromycin + metronidazole.
• Levofloxacin triple therapy – for retreatment.
• Common side effects – taste changes (metallic), diarrhea, nausea, black stools (bismuth – normal).
• Complete entire course to prevent resistance.
• Test of cure 4 weeks after antibiotic completion.

Diabetes Considerations

• Some studies suggest 1.5x higher H pylori in diabetes.
• Mechanisms – chronic inflammation, gut microbiome changes.
• May modestly worsen glycemic control if untreated.
• Eradication may modestly improve A1C.
• NOT recommended for routine screening in asymptomatic diabetes.
• DO test if symptoms or risk factors present.
• Long-term PPI use in diabetes – watch for B12 deficiency.
• Antibiotic treatment – monitor blood sugar (illness stress).
• CGM helpful during treatment.
• Consider metformin GI side effects vs H pylori symptoms.

Alarm Features (Warrant Endoscopy First)

• Age 60 or older with new dyspepsia.
• Unintentional weight loss.
• Persistent vomiting.
• Dysphagia (difficulty swallowing).
• GI bleeding (vomiting blood, black stools).
• Iron deficiency anemia (unexplained).
• Abdominal mass.
• Family history of gastric cancer.

Test Preparation

• Urea breath test – off PPIs 2 weeks (esomeprazole, omeprazole, others).
• Off H2 blockers (ranitidine, famotidine) 1-2 days.
• Off antibiotics 4 weeks before testing.
• Off bismuth subsalicylate (Pepto-Bismol) 4 weeks.
• Fast 1 hour before breath test.
• Stool antigen has similar preparation requirements.
• Serology – no preparation needed.
• Endoscopy – fast 8 hours; sedation; arrange ride.

The Bottom Line

Helicobacter pylori (H pylori) is a spiral-shaped bacterial infection of the stomach lining; one of the most common chronic infections worldwide. Prevalence – about 30-40% of U.S. adults; 50-70% in developing countries; often acquired in childhood. Most infections asymptomatic but can cause peptic ulcers (gastric, duodenal); chronic gastritis; gastric cancer (H pylori is Class I carcinogen); MALT lymphoma; possibly iron-deficiency anemia; possibly idiopathic thrombocytopenic purpura (ITP); functional dyspepsia in some. Indications for testing – active peptic ulcer disease; history of peptic ulcers; dyspepsia in adults under 60 without alarm features; long-term NSAID or aspirin therapy; family history of gastric cancer; gastric MALT lymphoma; unexplained iron-deficiency anemia; ITP; immigrants from high-prevalence countries with dyspepsia. After treatment – “test of cure” 4 weeks after antibiotic completion. Multiple test methods – urea breath test (very accurate 95%; good for diagnosis and test of cure); stool antigen test (very accurate; convenient; good for diagnosis and test of cure); blood antibody test (can’t distinguish active vs past; not for test of cure; less useful); endoscopy with biopsy (most invasive; for symptoms warranting endoscopy). Preparation – urea breath test and stool antigen need to be off PPIs 2 weeks, off antibiotics 4 weeks, off bismuth 4 weeks. Emerging area of research with mixed evidence about diabetes connection. Some studies suggest higher H pylori prevalence in adults with type 2 diabetes (about 1.5x more common); H pylori infection associated with worse glycemic control; eradication may modestly improve A1C; possible link to insulin resistance. Mechanisms proposed – chronic inflammation affecting insulin sensitivity; gut microbiome changes; effect on incretin hormones; altered absorption of nutrients. However – evidence inconsistent; routine screening NOT currently recommended just because of diabetes. American Diabetes Association does not recommend routine H pylori screening for asymptomatic diabetes patients. Reasonable scenarios for testing in diabetes – dyspepsia symptoms; long-term metformin causing GI symptoms (rule out other causes); on PPI long-term; family history of gastric cancer; failed dyspepsia treatment. Antibiotic treatment regimens – bismuth quadruple therapy (preferred first-line in many regions); clarithromycin triple therapy (where resistance is low); concomitant therapy; sequential therapy. Common side effects – taste changes, diarrhea, nausea, black stools (bismuth). Complete entire course to prevent resistance. Test of cure 4 weeks after antibiotic completion using urea breath test or stool antigen (NOT serology). Eradication rate 70-90% first attempt. For adults with diabetes – test if dyspepsia, ulcer history, or other indication; monitor blood sugar during antibiotic treatment; eradication may modestly improve glucose control; routine screening for asymptomatic diabetes not recommended. See our broader prediabetes detection guide.

A sleep study (polysomnography, PSG) is an overnight monitoring of sleep to diagnose sleep disorders, primarily sleep apnea. Two main types – in-lab polysomnography (PSG) is comprehensive overnight study at sleep lab; multiple sensors attached (brain waves/EEG, eye movements, muscle activity, breathing flow and effort, chest/abdomen movement, blood oxygen, heart rhythm, leg movements); video monitoring; sleep technician supervises; gold standard. Home sleep apnea test (HSAT) is simpler portable device; measures breathing, oxygen, heart rate; less comprehensive than PSG; more accessible and lower cost; reasonable for most uncomplicated sleep apnea cases. Information collected – sleep stages, breathing patterns, blood oxygen, heart rate, leg movements, snoring, apneas (breathing stops), hypopneas (shallow breaths). Diagnosis – apnea-hypopnea index (AHI) – events per hour of sleep. AHI categories – normal (less than 5), mild (5-14), moderate (15-29), severe (30+). For diabetes patients – screening recommended given very high prevalence. Major and undertreated comorbidity. Prevalence in type 2 diabetes – about 70% have obstructive sleep apnea (OSA); 50% have moderate to severe OSA; only 25% are diagnosed and treated. Bidirectional relationship – OSA worsens diabetes (insulin resistance, glucose control), and diabetes makes OSA worse (obesity, autonomic neuropathy). Effects of untreated OSA on diabetes – worse insulin resistance and glycemic control (mechanisms include intermittent hypoxia, sleep fragmentation, sympathetic activation); higher A1C (studies show 0.5-1.0% higher A1C in untreated OSA); more cardiovascular disease (already main cause of death in diabetes, OSA adds significant risk); higher blood pressure; higher mortality; more diabetic complications; daytime fatigue (affects self-management); higher hypoglycemia risk (sleep disturbance affects awareness). Treatment – CPAP (most effective), weight loss, oral appliances, surgery in some cases. CPAP adherent use shows modest A1C improvement, BP improvement, daytime function improvement. American Diabetes Association recommends consideration of sleep apnea screening for adults with type 2 diabetes given high prevalence. Specific indications – symptoms of OSA (loud snoring witnessed by partner, witnessed apneas – breathing stops, gasping/choking during sleep, excessive daytime sleepiness, morning headaches, dry mouth on waking); STOP-BANG screening questions; resistant hypertension; uncontrolled diabetes despite good adherence; heart failure or atrial fibrillation; stroke history; pulmonary hypertension. Many adults with diabetes go years undiagnosed – low threshold for screening recommended.

Sleep Apnea in Diabetes

AHI Severity Categories

STOP-BANG Screening

• Snoring loudly? (Heard through closed door, partner complaint)
• Tired during day? (Daytime sleepiness)
• Observed apneas? (Partner witnessed breathing stops)
• Pressure (high blood pressure)?
• BMI greater than 35?
• Age over 50?
• Neck circumference larger than 16 inches?
• Gender male?
• 3+ “yes” – high risk; consider testing.

OSA Symptoms

• Loud snoring (especially with pauses).
• Witnessed apneas – breathing stops.
• Gasping or choking during sleep.
• Excessive daytime sleepiness.
• Morning headaches.
• Dry mouth on waking.
• Restless sleep (frequent movements).
• Difficulty concentrating during day.
• Mood changes (irritability, depression).
• Decreased libido or sexual dysfunction.
• Nocturia (waking to urinate).
• Falling asleep while driving or working.
• Memory problems.

OSA Effects on Diabetes

• Worse insulin resistance and glucose control.
• Higher A1C (0.5-1.0% higher in untreated OSA).
• More cardiovascular disease.
• Higher blood pressure (often resistant).
• Higher mortality.
• More diabetic complications (retinopathy, neuropathy, nephropathy).
• Daytime fatigue affecting self-management.
• Higher hypoglycemia risk (impaired awareness).
• Worse quality of life.
• Higher healthcare costs.

Treatment Options

• CPAP (continuous positive airway pressure) – most effective; nightly mask.
• BiPAP (bilevel) – for some patients.
• APAP (auto-titrating CPAP) – most common modern device.
• Oral appliances (mandibular advancement) – for mild-moderate OSA.
• Weight loss – significant benefit; bariatric surgery in some cases.
• Positional therapy – back-sleeping causes OSA in some.
• Surgery – uvulopalatopharyngoplasty (UPPP), Inspire hypoglossal stimulation.
• Sleep hygiene improvements.
• Avoid alcohol before bed.
• Treat nasal congestion.
• Side-sleeping aids.

The Bottom Line

A sleep study (polysomnography, PSG) is an overnight monitoring of sleep to diagnose sleep disorders, primarily sleep apnea. Two main types – in-lab polysomnography (comprehensive overnight study at sleep lab; multiple sensors; gold standard) and home sleep apnea test (HSAT – simpler portable device; reasonable for most uncomplicated cases). Information collected – sleep stages, breathing patterns, blood oxygen, heart rate, leg movements, snoring, apneas, hypopneas. Diagnosis – apnea-hypopnea index (AHI) – events per hour of sleep. AHI categories – normal (less than 5), mild (5-14), moderate (15-29), severe (30+). Major and undertreated comorbidity in diabetes. Prevalence in type 2 diabetes – about 70% have obstructive sleep apnea (OSA); 50% have moderate to severe OSA; only 25% are diagnosed and treated. Bidirectional relationship – OSA worsens diabetes (insulin resistance, glucose control), and diabetes makes OSA worse (obesity, autonomic neuropathy). Effects of untreated OSA on diabetes – worse insulin resistance and glycemic control; higher A1C (0.5-1.0% higher); more cardiovascular disease; higher blood pressure; higher mortality; more diabetic complications; daytime fatigue; higher hypoglycemia risk. American Diabetes Association recommends consideration of sleep apnea screening for adults with type 2 diabetes given high prevalence. Specific indications – symptoms of OSA (loud snoring, witnessed apneas, gasping/choking during sleep, excessive daytime sleepiness, morning headaches); STOP-BANG screening (3+ “yes” – high risk); resistant hypertension; uncontrolled diabetes despite good adherence; heart failure or atrial fibrillation; stroke history. Many adults with diabetes go years undiagnosed – low threshold for screening recommended. In-lab polysomnography – arrive evening; multiple sensors attached; sleep in private room; technician monitors all night; about 8-10 hours. Home sleep test – simpler kit at home; few sensors. CPAP treatment – if diagnosed; nightly mask worn during sleep; gentle positive air pressure keeps airway open; multiple mask types; results with adherent use – improved sleep quality, daytime function, blood pressure, diabetes control. Alternatives if CPAP intolerant – oral appliances, positional therapy, surgery, weight loss. Compliance tracked by machine; insurance may require 70% use 4+ hours per night. Treatment options – CPAP (most effective), BiPAP, APAP (auto-titrating most common modern device), oral appliances (mandibular advancement for mild-moderate), weight loss (significant benefit), positional therapy, surgery (UPPP, Inspire hypoglossal stimulation), sleep hygiene improvements. For adults with type 2 diabetes – sleep apnea screening should be considered if STOP-BANG positive or symptoms present; untreated OSA worsens diabetes outcomes substantially; CPAP treatment effective and improves diabetes control with adherent use. See our broader sleep apnea and diabetes guide for context.

A falls risk assessment is a structured evaluation of factors that increase a person’s risk of falling. Multiple components – brief screening questions (“Have you fallen in the past year?” “Do you feel unsteady when standing or walking?” “Are you worried about falling?” – any “yes” = increased risk); medical history review (prior falls, fractures, fear of falling, medications, vision, hearing, conditions affecting balance); physical assessment (blood pressure sitting and standing looking for orthostatic hypotension, vision test, gait observation, balance tests like Timed Up and Go test); environmental review (home hazards); medication review (sedatives, anticholinergics, antihypertensives, hypoglycemia-causing diabetes meds); footwear assessment. STEADI (CDC) widely used algorithm screens, assesses, intervenes. American Diabetes Association recommends fall risk evaluation as part of annual diabetes care for older adults. Multiple diabetes complications increase risk. Studies show 1.5-2x higher fall risk in adults with diabetes vs without. Diabetes-specific factors – peripheral neuropathy (reduced sensation in feet/lower legs; impaired proprioception; balance affected; affects 40-50% of long-duration diabetes); autonomic neuropathy (orthostatic hypotension – BP drop on standing causing dizziness/falls; 20-30% of diabetes patients); retinopathy (visual impairment; reduced contrast sensitivity, depth perception); cataracts (4x more common in diabetes; affect vision); hypoglycemia (sudden weakness, dizziness, confusion; causes falls); polypharmacy (multiple medications including insulin, sulfonylureas, blood pressure meds, statins, often multiple); foot complications (charcot foot, calluses, ulcers affecting gait); sarcopenia (muscle loss more common in long-duration diabetes); cognitive impairment (mild cognitive impairment 2x more common in diabetes); fear of falling itself increases falls. Combined effect – older adults with diabetes need active fall prevention. Multifaceted intervention based on identified risks. STEADI 3-step framework – SCREEN (brief questions), ASSESS (full evaluation if positive), INTERVENE (address modifiable factors). Specific interventions for diabetes patients – diabetes management (prevent hypoglycemia especially with insulin/sulfonylurea users; consider deintensification in older adults; CGM helpful); maintain A1C 7-8% in older adults (avoid tight control causing hypoglycemia); vision (annual comprehensive eye exam, cataract surgery if affecting vision, updated glasses); foot care (regular foot exams, orthotics, appropriate footwear, treat neuropathy); exercise (balance training – tai chi has best evidence, strength training, aerobic exercise); medication review; vitamin D supplementation if deficient; home safety; use cane or walker if balance issues; address orthostatic hypotension; manage cognitive concerns.

STEADI 3 Key Questions (CDC Screening)

Diabetes-Specific Fall Risk Factors

Common Assessment Tools

• STEADI 3-question screen (CDC).
• Timed Up and Go (TUG) – over 12 seconds suggests risk.
• 30-second chair stand test – strength assessment.
• 4-stage balance test (feet together, semi-tandem, tandem, single-leg).
• Tinetti POMA (Performance Oriented Mobility Assessment).
• Berg Balance Scale (14-item; PT/research).
• Functional Reach Test (forward reach distance).
• Morse Fall Scale (inpatient).
• Annual fall history review.

Fall Prevention Interventions

• Exercise – balance training (tai chi best evidence), strength training, walking.
• Medication review – eliminate unnecessary meds; switch high-risk to lower-risk.
• Vision – annual eye exam, cataract surgery if needed, updated glasses.
• Hearing – hearing test, hearing aids if needed.
• Foot care – regular foot exams, podiatry, orthotics, proper footwear.
• Home safety – remove rugs, improve lighting, install grab bars, eliminate clutter.
• Vitamin D supplementation if deficient.
• Address orthostatic hypotension (slow position changes, hydration).
• Use cane or walker if balance issues.
• Prevent hypoglycemia (especially insulin/sulfonylurea users).
• Maintain A1C 7-8% in older adults (avoid tight control).
• CGM device to detect/prevent hypoglycemia.
• Address cognitive concerns.
• Address fear of falling (cognitive behavioral approaches).

Home Safety Checklist

• Remove or secure throw rugs.
• Clear walkways of clutter.
• Adequate lighting throughout home.
• Night lights in bedroom, bathroom, hallway.
• Stair handrails on both sides.
• Mark stair edges with bright tape.
• Grab bars in bathroom (shower, toilet).
• Non-slip mats in shower/tub.
• Shower chair if needed.
• Raised toilet seat if needed.
• Cordless phone or medical alert system.
• Frequently used items within easy reach.
• Cords organized, not in walkways.
• Outdoor walkways well-lit and even.

The Bottom Line

A falls risk assessment is a structured evaluation of factors that increase a person’s risk of falling. Multiple components – brief screening questions (“Have you fallen in the past year?” “Do you feel unsteady when standing or walking?” “Are you worried about falling?”); medical history review; physical assessment (blood pressure sitting and standing, vision test, gait observation, balance tests like Timed Up and Go); environmental review; medication review; footwear assessment. STEADI (CDC) widely used algorithm screens, assesses, intervenes. American Diabetes Association recommends fall risk evaluation as part of annual diabetes care for older adults. Multiple diabetes complications increase risk. Studies show 1.5-2x higher fall risk in adults with diabetes vs without. Diabetes-specific factors – peripheral neuropathy (reduced sensation in feet/lower legs; impaired proprioception; affects 40-50% of long-duration diabetes); autonomic neuropathy (orthostatic hypotension – BP drop on standing; 20-30% of patients); retinopathy (visual impairment); cataracts (4x more common); hypoglycemia (sudden weakness, dizziness, confusion); polypharmacy; foot complications; sarcopenia; cognitive impairment; fear of falling itself. Older adults with diabetes need active fall prevention. STEADI 3-step framework – SCREEN, ASSESS, INTERVENE. Specific interventions for diabetes patients – diabetes management (prevent hypoglycemia especially with insulin/sulfonylurea users; consider deintensification in older adults; CGM helpful); maintain A1C 7-8% in older adults (avoid tight control causing hypoglycemia); vision (annual comprehensive eye exam, cataract surgery, updated glasses); foot care; exercise (balance training – tai chi has best evidence, strength training, aerobic exercise); medication review; vitamin D supplementation if deficient; home safety; use cane or walker if balance issues; address orthostatic hypotension; manage cognitive concerns. Multiple assessment tools – STEADI 3-question screen, Timed Up and Go (over 12 seconds suggests risk), 30-second chair stand test, 4-stage balance test, Tinetti POMA, Berg Balance Scale. For adults with type 2 diabetes – annual fall risk screening especially after age 65; address modifiable factors aggressively; prevent hypoglycemia; manage diabetic complications; exercise for balance and strength; home safety modifications; report falls or balance concerns to healthcare team promptly. See our broader diabetes complications guide for context.

Visual acuity testing measures how clearly you see at various distances. Standard tests – Snellen chart (row of letters of decreasing size; you read smallest line possible at 20 feet distance; results expressed as 20/20 normal, 20/40, 20/200 legal blindness); Tumbling E (for children or non-readers); LogMAR chart (more standardized; used in research/clinical trials); near vision card (reading test card at 14 inches). Visual acuity alone doesn’t show all vision problems – peripheral vision, color vision, contrast sensitivity, depth perception, eye health all require additional tests. For adults with diabetes – acuity alone is insufficient; comprehensive eye exam including dilated retinal exam, intraocular pressure measurement, peripheral vision testing, examination of all eye structures essential annually. Refraction determines the eyeglass prescription. Process – measures how light bends through your eye and what corrective lens needed. Components – objective refraction (autorefractor or retinoscopy) – machine measures basic prescription quickly; subjective refraction (phoropter) – “which is better, 1 or 2?” comparisons; fine-tunes prescription based on patient response. Measurements – sphere (nearsightedness or farsightedness), cylinder (astigmatism), axis (astigmatism direction), add (reading correction for presbyopia). Common conditions – myopia (nearsightedness), hyperopia (farsightedness), astigmatism (uneven curvature), presbyopia (age-related near vision decline starting 40s). For adults with diabetes – prescription can fluctuate with blood sugar levels (lens swells with hyperglycemia, shrinks with normalization); WAIT 4-6 weeks after starting diabetes treatment before new glasses prescription; recheck after blood sugar stabilizes. Multiple effects requiring comprehensive eye care – acute hyperglycemia causes lens swelling and temporary blurry vision (resolves with blood sugar control); cataracts develop earlier and progress faster in diabetes (4x more common in younger adults); glaucoma 2x more common in diabetes; diabetic retinopathy (most common eye complication; damage to retinal blood vessels; can cause blindness if untreated; requires dilated retinal exam); diabetic macular edema (swelling of central retina; major cause of vision loss in diabetes); optic neuropathy (rare diabetic complication). American Diabetes Association recommendations – comprehensive dilated eye exam at diagnosis (type 2) or within 5 years (type 1); annual screening thereafter; more frequent if retinopathy present. Comprehensive exam includes – visual acuity, refraction, IOP, dilated retinal exam, slit lamp exam of front of eye, peripheral vision (when indicated).

Visual Acuity Categories

Components of Comprehensive Eye Exam

Diabetes-Related Eye Conditions

• Acute hyperglycemia – temporary blurry vision; lens swells.
• Cataracts – 4x more common in diabetes; cloudy lens; surgery fixes.
• Glaucoma – 2x more common; gradual peripheral vision loss.
• Diabetic retinopathy – leading cause of new blindness in working-age adults.
• Diabetic macular edema – swelling of central retina.
• Optic neuropathy – rare diabetic complication.
• Dry eye – more common in diabetes.
• Eye muscle problems (cranial nerve palsies) – usually transient.
• Iris neovascularization – severe diabetic eye complication.

When to See Eye Care Provider

• Annual comprehensive dilated eye exam (ADA recommendation).
• Sudden vision change – urgent.
• New floaters or flashing lights – urgent.
• Curtain or shadow in vision – urgent.
• Eye pain – urgent.
• Persistent blurry vision (not blood sugar fluctuation).
• Difficulty seeing at night.
• Trouble adjusting between light and dark.
• Halos around lights.
• Pregnancy with diabetes – exam each trimester.
• After significant blood sugar changes – recheck refraction.

Tips for Adults with Diabetes

• Schedule annual comprehensive dilated exam.
• Wait 4-6 weeks after blood sugar normalization before new glasses prescription.
• Maintain A1C in target range to slow eye complications.
• Control blood pressure (impacts retinopathy).
• Control cholesterol.
• Don’t smoke.
• Wear UV-blocking sunglasses outdoors.
• Inform eye doctor of all diabetes medications.
• Bring blood sugar log to appointments.
• Promptly report new symptoms.
• Take photographs of eye exams (fundus photos) for records.

The Bottom Line

Visual acuity testing measures how clearly you see at various distances. Standard tests – Snellen chart (row of letters of decreasing size; you read smallest line possible at 20 feet distance; results expressed as 20/20 normal, 20/40, 20/200 legal blindness); Tumbling E for children or non-readers; LogMAR chart more standardized; near vision card at 14 inches. Visual acuity alone doesn’t show all vision problems – peripheral vision, color vision, contrast sensitivity, depth perception, eye health all require additional tests. For adults with diabetes – acuity alone is insufficient; comprehensive eye exam including dilated retinal exam, intraocular pressure measurement, peripheral vision testing, examination of all eye structures essential annually. Refraction determines the eyeglass prescription. Components – objective refraction (autorefractor or retinoscopy); subjective refraction (phoropter) – “which is better, 1 or 2?” comparisons. Measurements – sphere (nearsightedness or farsightedness), cylinder (astigmatism), axis, add (reading correction for presbyopia). Common conditions – myopia, hyperopia, astigmatism, presbyopia. For adults with diabetes – prescription can fluctuate with blood sugar levels (lens swells with hyperglycemia, shrinks with normalization); WAIT 4-6 weeks after starting diabetes treatment before new glasses prescription; recheck after blood sugar stabilizes. Multiple effects of diabetes requiring comprehensive eye care – acute hyperglycemia causes lens swelling and temporary blurry vision; cataracts develop earlier and progress faster in diabetes (4x more common in younger adults); glaucoma 2x more common; diabetic retinopathy (most common eye complication; can cause blindness if untreated); diabetic macular edema; optic neuropathy. American Diabetes Association recommendations – comprehensive dilated eye exam at diagnosis (type 2) or within 5 years (type 1); annual screening thereafter; more frequent if retinopathy present. Comprehensive exam includes visual acuity, refraction, IOP, dilated retinal exam, slit lamp exam of front of eye, peripheral vision. Comprehensive 30-90 minute appointment. Preparation – bring current glasses or contact lenses; bring sunglasses (for after dilation); arrange transportation if dilation expected; list current medications and recent blood sugar values. Procedure components – visual acuity test, visual field screening, eye muscle test, pupil response check, refraction, intraocular pressure measurement, slit lamp exam, dilation drops applied, dilated retinal exam, OCT scan often performed, fundus photography may be done. After exam – blurry vision and light sensitivity 4-6 hours from dilation; can’t drive immediately. For adults with diabetes – ensure all components performed; ask about findings specifically (retinopathy grade if any, macular status); wait 4-6 weeks after blood sugar normalization before new glasses prescription; maintain A1C in target range to slow eye complications; control blood pressure and cholesterol; don’t smoke; wear UV-blocking sunglasses outdoors; report new symptoms promptly. See our broader prediabetes detection guide.